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Abstract
Bacterial virulence factors enable a host to replicate and
disseminate within a host in part by subverting or eluding host
defenses. The use of genomic techniques has led to the
identification of new virulence factors that may serve as targets for
new therapies. These putative virulence factors must be rigorously
evaluated with in vitro and in vivo studies with an awareness of the
technical limitations of each approach as well as an assessment of
the prevalence of this factor in clinical bacterial isolates retrieved
from appropriately controlled epidemiologic studies.
Infections are a leading cause of death in the intensive care
unit. With the rising incidence of bacteria resistant to multiple
antibiotics and a decreasing antibiotic drug pipeline,
clinicians have sought additional therapies to supplement the
current standard of care. Originally, such therapies, including
anti-endotoxin antibodies and intravenous immunoglobulin,
targeted the causative organisms. However, these efforts
were supplanted by efforts to modulate the host responses to
these organisms that were considered to be responsible for
sepsis. Despite extensive clinical trials with biologic response
modifiers, there is only one intervention licensed by the US
Food and Drug Administration, drotrecogin alpha (Xigris®).
Consequently, attention has now returned toward targeting
the organisms. This development has been greatly assisted
by the advent of genomics and systems biology, which have
led to the identification of previously unrecognized targets on
bacteria. These disciplines, in conjunction with advances in
molecular biologic techniques, have led to striking advances
in our understanding of the molecular pathogenesis of
infection and the role of an ever-widening array of potential
bacterial virulence factors. In their comprehensive review in
this issue of Critical Care, Webb and Kahler [1] speculate
that targeting virulence may be an attractive therapeutic
strategy. Leaving aside the issues of drug formulation and/or
delivery, what is required for the identification of a ‘drugable’
virulence target?
Pathogens are perhaps the pre-eminent cell biologists, having
over the span of millennia identified special niches or
strategies, not only to subvert host defenses, but in some
instances (like the polysialic acid K1 capsule of Escherichia
coli) to elude detection through bacterial mimicry (by which
the bacterial ‘wolf’ wraps itself in the ‘sheep’s clothing’ of the
host’s cell). As these authors point out, many of the virulence
mechanisms are now defined at precise molecular and
genetic levels. However, the likelihood of developing
therapies that target such virulence factors will depend on
subsequent rigorous experimentation. With in vitro studies,
one can precisely delineate the mechanism of a putative
virulence factor in a cellular phenotype of interest, but these
studies are unable to assess the effect of a virulence
determinant on more complex intercellular interactions. These
studies often employ non-physiologic levels of the molecule
of interest, accompanied by non-physiologic exposure times.
Such long exposure times make it difficult to separate the
early, primary effects of the virulence factor from those later
effects (for example, at 24 hours) caused by secondary
biologic cascades and/or the accumulation of mediators.
Consequently, it is necessary to complement in vitro with in
vivo studies, but these, too, are fraught with technical pitfalls.
To the authors’ definition of virulence (ability to enter,
replicate, and persist in a host), a virulence factor must
enable the organism to do so with a relatively small inoculum.
Simply giving high bacterial inocula that overcome host
defenses does not allow one to make any determination of
the importance of a virulence factor [2]. The route of bacterial
administration is also critical [3]. Although it may be counter-
intuitive, administration of bacteria by the intravenous route
results in a far greater LD50 (median lethal dose) than when
that same organism is administered either intraperitoneally or
subcutaneously. Potent host defenses and clearance
mechanisms are arrayed along the vasculature that clear the
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bloodstream of not only live bacteria but also inert particles.
In the case of either intraperitoneal or subcutaneous challenge,
there follows a ‘race’ between the ability of a pathogen to
replicate at that site and the recruitment of host defenses.
Virtually every clinical bacteremic isolate, both Gram-positive
and -negative, is serum-resistant [4]. As the authors acknow-
ledge, lipopolysaccharide (LPS) and capsular phenotypes are
the pre-eminent virulence determinants of Gram-negative
bacteria. With the possible exception of bacteria on mucosal
surfaces, strains of E. coli that lack a ‘bacteremic phenotype’
are highly avirulent [4]. For example, when 1010 colony-
forming units of an enteropathogenic strain of E. coli, such as
O111, which is rarely found in the blood, were given
intravenously to baboons, the organism was cleared quickly
with little dissemination [5]. This observation has practical
significance in evaluating putative virulence factors: the
addition of a recognized virulence determinant, K1 capsule,
into a deep rough LPS background did not confer any
virulence to the organism [6]. This observation illustrates that,
with the exception of some bacterial exotoxins, such as
tetanus, diphtheria, and botulinus toxins, it is unusual for a
single bacterial virulence factor by itself to initiate disease.
Finally, the importance of the O antigen and capsular
polysaccharides as virulence determinants can be demon-
strated by the fact that antibodies directed against the O
antigens of Gram-negative bacteria are highly protective [7,8]
and that many of the licensed vaccines against bacterial
pathogens are directed against the capsular polysaccharides.
These antigens are constitutively expressed, accessible, and
rarely subject to change. Of the more than 150 O serogroups
of E. coli, 10 to 12 serogroups account for most cases of
invasive infection, and of the more than 100 capsular poly-
saccharides, K1 is found in 20% of cases in adults [8]. This
observation demonstrates another necessity in defining a
‘drugable’ virulence factor. Following both in vitro and in vivo
studies, one must assess whether that virulence determinant
can be found in bacteria retrieved from an appropriate clinical
population. There is one caveat: if a virulence factor mimics a
critical host molecule, therapeutic targeting of such a
molecule risks harming the host. For example, the polysialic
acid capsule of group B meningococci mimics molecules
present on the surface of developing human brain cells [9].
This consideration has had a profound impact on the
development of meningococcal vaccines.
It is both timely and appropriate that Webb and Kahler re-focus
attention on targeting the bacteria. Although we now have
potent molecular tools for identifying novel virulence determi-
nants, they must be evaluated by complementary in vitro and in
vivo studies and supported by relevant clinical observations
and an awareness of the pitfalls of each approach.
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